Black Ginger, Erectile Function and the PDE5 Claim: Doing the Arithmetic

This is the claim that sells the most black ginger, and it is the one most worth slowing down on, because the underlying science is real — a peer-reviewed enzyme finding, published in a respectable pharmacology journal — and the marketing conclusion drawn from it is not what the paper says. The word doing all the work is "low affinity," and it is nearly always dropped between the study and the sales page.

Table of Contents

  1. What Is Actually Being Claimed
  2. The Enzyme Finding: Real, and Explicitly "Low Affinity"
  3. The Arithmetic: How Far Below Sildenafil?
  4. Why an IC50 Is Not a Clinical Effect
  5. Vascular Tissue and Blood-Fluidity Work
  6. The Human Trial: One Open-Label Pilot
  7. Why Erectile-Function Questionnaires Are Especially Placebo-Prone
  8. The Name That Makes the Claim Isn't the Plant's Own Name
  9. New-Onset ED Is a Medical Symptom, Not Just an Inconvenience
  10. The Same Mechanism That Makes the Claim Is Why It Interacts With the Real Drug
  11. Numbers This Page Refuses to Give
  12. Evidence Ledger for This Claim
  13. Practical Bottom Line
  14. Key Research Papers
  15. Connections

What Is Actually Being Claimed

Black ginger is routinely described online as a "natural Viagra" or "herbal PDE5 inhibitor." Unpacked, that is actually three claims stacked on top of each other, and only the first has real laboratory support:

  1. Black ginger contains compounds that inhibit PDE5 in a test tube. True, published, replicated. Covered in detail below.
  2. An oral dose of black ginger inhibits PDE5 enough, in the relevant tissue, to matter clinically — the way a dose of sildenafil does. Not demonstrated. This is the gap the rest of this page is about.
  3. Black ginger improves erectile function in men who take it. Tested exactly once, in a design that cannot actually answer the question. Covered below.

Marketing copy moves from claim 1 to claim 3 in a single sentence. The actual evidence does not.

The Enzyme Finding: Real, and Explicitly "Low Affinity"

The source of the whole claim is a single 2011 paper: Temkitthawon and colleagues, published in the Journal of Ethnopharmacology, and its title is honestly the whole story if you read past the first half — "Kaempferia parviflora, a plant used in traditional medicine to enhance sexual performance, contains large amounts of low affinity PDE5 inhibitors." PDE5, phosphodiesterase type 5, is the enzyme that breaks down cyclic GMP in vascular smooth muscle, including the smooth muscle of the penis. Blocking PDE5 lets cyclic GMP accumulate, which relaxes smooth muscle and allows blood to flow in — this is literally how sildenafil (Viagra), tadalafil (Cialis) and vardenafil (Levitra) work.

Testing extracts and isolated compounds from the rhizome against purified PDE5 in an enzyme assay, the authors found real inhibitory activity. The most potent single compound was 5,7-dimethoxyflavone (5,7-DMF), with a reported IC50 of approximately 10.6 µM against PDE5 — the concentration required to block half of the enzyme's activity. A second methoxyflavone in the same series was weaker still, with a reported IC50 in the region of 30 µM. Both numbers are real, both are published, and both fully justify the paper's own word for what it found: low affinity. A lower IC50 means a more potent inhibitor; these are not low numbers.

Back to Table of Contents

The Arithmetic: How Far Below Sildenafil?

This is the comparison the marketing never makes, and it can be made honestly because sildenafil's own enzymology is one of the most thoroughly characterised numbers in pharmacology. Boolell and colleagues' original 1996 characterisation reported sildenafil's IC50 against PDE5 at approximately 3.9 nanomolar (0.0039 µM) — a figure confirmed and re-confirmed across three decades of subsequent PDE5-inhibitor research.

Put the two numbers on the same scale and the gap is stark. Dividing black ginger's best reported IC50 by sildenafil's:

10.6 µM ÷ 0.0039 µM ≈ 2,700
30 µM ÷ 0.0039 µM ≈ 7,700

By this arithmetic, the most potent compound black ginger contains needs to be present at roughly 2,700 times the concentration that sildenafil needs to achieve the same degree of enzyme inhibition; the second, weaker compound needs almost 7,700 times the concentration. That is not "similar potency, natural source" — it is a gap of more than three orders of magnitude, and it is the actual, citable meaning of the word "low affinity" in the paper's own title. Print the assumption plainly: this comparison takes both IC50 figures directly from their respective published sources and compares them on the same molar scale; it does not correct for any difference in assay conditions between the two papers, which could move the exact ratio somewhat but would not close a gap this large.

Why an IC50 Is Not a Clinical Effect

A drug's real-world effect depends on whether it reaches its inhibitory concentration in the target tissue, not on what an enzyme assay shows in a dish. Sildenafil's 3.9 nM potency, combined with its absorption and distribution, means a standard 50 mg oral tablet reliably reaches meaningful PDE5 inhibition in penile tissue — this is precisely what a clinical drug-development programme is designed to establish, dose by dose, before a drug is approved. Nobody has measured methoxyflavone concentration in human penile tissue after an oral dose of black ginger extract, and given that its best compound needs roughly 2,700 times the concentration sildenafil needs, the burden of proof for "a normal capsule gets there" is substantial and currently entirely unmet. Citing an in-vitro IC50 as though it were a demonstrated clinical effect is one of the single most common ways supplement marketing misuses real pharmacology — the number is not fabricated, the leap from the number to the claim is.

Vascular Tissue and Blood-Fluidity Work

Beyond the enzyme assay, there is genuine supporting pharmacology at the tissue level, and it deserves to be reported on its own terms rather than folded into the PDE5 story.

Tep-Areenan and colleagues showed that isolated 5,7-DMF relaxes pre-contracted rat aortic rings in an organ bath and probed the mechanism behind it. Yorsin and colleagues later reported that six weeks of oral dosing with a related trimethoxyflavone raised vascular eNOS (endothelial nitric oxide synthase) and cystathionine-γ-lyase (a hydrogen-sulfide-producing enzyme, itself a vasodilator pathway) protein levels in treated animals — a second, independent vasodilatory mechanism alongside PDE5 inhibition. Separately, Murata and colleagues reported that the rhizome shortened blood passage time through a micro-slit device in a disseminated-intravascular-coagulation animal model, attributing the effect to activation of fibrinolysis (clot breakdown).

All three findings are genuine pharmacology, and all three are isolated tissue or whole-animal work, with no human correlate measured. They also matter for a second reason that has nothing to do with the benefit claim: a plant that measurably relaxes vascular smooth muscle by two independent mechanisms and activates fibrinolysis is a plant to think about before surgery, and a plant that plausibly interacts with drugs and conditions affecting clotting and blood pressure. See Methoxyflavone Chemistry and Drug Interactions for the fuller safety picture that follows from this same mechanism.

The Human Trial: One Open-Label Pilot

There is exactly one published human study of black ginger for sexual function: Stein and colleagues, 2018. Fourteen generally healthy men aged 50–68, with self-reported mild erectile dysfunction, took 100 mg of a branded ethanol extract daily for 30 days and completed the International Index of Erectile Function (IIEF) questionnaire and a global assessment question before and after.

List the design weaknesses plainly, because together they are close to a complete inventory of what can go wrong in a supplement trial:

The authors themselves describe the study as a pilot, which is the correct and honest label for it — a pilot is licence to run a properly controlled follow-up, not a result to act on. Eight years later, that follow-up has not appeared. A 2024 systematic review and meta-analysis by Na Takuathung and colleagues does report improvement in sexual function pooled across the available studies, but that pool is dominated by animal experiments, and its human component is this same small, uncontrolled trial — a meta-analysis cannot manufacture rigour that the underlying single study does not have.

Back to Table of Contents

Why Erectile-Function Questionnaires Are Especially Placebo-Prone

The IIEF itself is a legitimate, carefully validated instrument — Rosen and colleagues' 1997 development and validation paper established it as a reliable, cross-culturally consistent, multidimensional measure of erectile function, and it remains the standard outcome measure in ED drug trials to this day. The instrument is not the problem with the Stein study; the design around it is.

Erectile function is one of the more placebo-responsive outcomes in clinical medicine. Placebo arms in properly controlled ED drug trials routinely show meaningful IIEF score improvements — a combination of expectation, the attention and novelty of joining a trial, natural fluctuation in a symptom with strong psychological and relationship components, and regression to the mean in men enrolled during a bad stretch. A single-arm study with no placebo comparison cannot distinguish a real drug effect from this placebo response, no matter how good the questionnaire is. This is precisely why ED drug trials are placebo-controlled as standard practice, and precisely why a 30-day open-label pilot cannot be read as evidence that the herb, rather than the expectation of taking it, produced the reported improvement.

The Name That Makes the Claim Isn't the Plant's Own Name

It is worth noting an asymmetry that runs the opposite direction from most traditional herbs on this site. When a traditional name itself asserts an outcome — motherwort's implied action on the uterus, or hadjod, Cissus's "bone-joiner" — every unblinded observer already knows what the plant is supposed to do, which biases the very evidence base built on it. Black ginger's actual traditional name, Thai krachai dam, means simply "black krachai" — it describes the rhizome's colour and identity, not an effect. Checked against that pattern, the name comes back clear: it does not smuggle in a sexual-performance claim.

The claim instead lives entirely in the English-language marketing nickname — "Thai Viagra," "herbal Viagra," "natural Viagra" — which is not a translation of anything Thai and appears to be a modern commercial invention layered onto the plant well after the traditional name was already in use. That distinction matters for how much weight the tradition itself can bear: the centuries of use behind krachai dam support "warming tonic, taken by labourers and used in men's health preparations generally," which is the older and vaguer framing. They do not support "functions like a PDE5-inhibitor drug," which is a 21st-century marketing claim riding on a 2011 laboratory finding, not an inheritance from the tradition itself.

New-Onset ED Is a Medical Symptom, Not Just an Inconvenience

One point belongs on this page regardless of how the evidence above is weighed. The blood vessels of the penis are small, and endothelial dysfunction tends to show up there before it shows up in larger vessels — which is why new-onset erectile dysfunction, particularly in a man without an obvious situational cause, is a recognised early clinical marker for atherosclerosis, coronary artery disease and type 2 diabetes, sometimes years before either condition is otherwise diagnosed. Self-treating new-onset ED with any supplement, herbal or otherwise, without a medical evaluation risks missing that signal. This is not a hedge added out of caution — it is a specific, actionable clinical fact that a self-treatment approach forecloses, and it is a stronger reason to see a doctor first than any safety concern about the herb itself.

The Same Mechanism That Makes the Claim Is Why It Interacts With the Real Drug

There is a genuine irony worth stating plainly. The same methoxyflavones responsible for the PDE5 story also inhibit the liver enzyme CYP3A4 — and CYP3A4 is exactly the enzyme that metabolises sildenafil and tadalafil themselves (see Methoxyflavone Chemistry and Drug Interactions for the full evidence). A man who takes black ginger and a prescribed PDE5-inhibitor drug is not doubling down on the same weak mechanism — he may be raising blood levels of the actual potent drug, an effect with real clinical consequence, particularly in anyone also using nitrate medication for angina, where the combination of any PDE5 pathway activity with nitrates can cause a dangerous drop in blood pressure. See Angina for why nitrate use specifically rules out anything acting on this pathway.

Back to Table of Contents

Numbers This Page Refuses to Give

Evidence Ledger for This Claim

  1. PDE5 enzyme inhibition in vitro. Tier: established, replicated, low affinity by the original authors' own characterisation. Real chemistry, honestly reported by the people who found it; the distortion happens downstream in marketing, not in the paper.
  2. Vasorelaxation and fibrinolysis in isolated tissue and animals. Tier: consistent preclinical, multiple independent mechanisms (PDE5, eNOS/H2S pathway, fibrinolysis). Coherent and mechanistically interesting; also the direct evidentiary basis for the bleeding and surgery caution, not only the benefit claim.
  3. Improved erectile function in humans. Tier: one small, uncontrolled, unblinded, industry-run pilot study — positive but structurally unable to separate drug effect from placebo. This is the doctrine's third verdict in practice: not absent (a trial exists), not a confirmed negative (no adequately controlled trial has failed), but a weak, uncontrolled positive that cannot bear the weight placed on it. Calling it either "no evidence" or "clinically shown" misdescribes it.
  4. Clinical potency comparable to an approved PDE5-inhibitor drug. Tier: refuted by the herb's own primary source data. The 2,700-to-7,700-fold IC50 gap is not a matter of interpretation; it is arithmetic on two published numbers.

Practical Bottom Line

Key Research Papers

Every citation is a PubMed search built from author names and distinctive title words, pre-checked against the live NCBI database before this page was written, rather than a numeric identifier.

  1. Temkitthawon P, Hinds TR, Beavo JA, Viyoch J, et al. Kaempferia parviflora, a plant used in traditional medicine to enhance sexual performance contains large amounts of low affinity PDE5 inhibitors. Journal of Ethnopharmacology, 2011. The source of the whole claim; read the title in full. Find on PubMed.
  2. Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. International Journal of Impotence Research, 1996. The source of the 3.9 nM comparison figure. Find on PubMed.
  3. Stein RA, Schmid K, Bolivar J, Swick AG, et al. Kaempferia parviflora ethanol extract improves self-assessed sexual health in men: a pilot study. Journal of Integrative Medicine, 2018. The only human trial; read the limitations section. Find on PubMed.
  4. Rosen RC, Riley A, Wagner G, Osterloh IH, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology, 1997. The validated instrument used in the Stein pilot. Find on PubMed.
  5. Tep-Areenan P, Sawasdee P, Randall M. Possible mechanisms of vasorelaxation for 5,7-dimethoxyflavone from Kaempferia parviflora in the rat aorta. Phytotherapy Research, 2010. Find on PubMed.
  6. Yorsin S and colleagues. Increased vascular eNOS and cystathionine-γ-lyase protein after oral administration of a Kaempferia parviflora methoxyflavone. Naunyn-Schmiedeberg's Archives of Pharmacology, 2016. A second, independent vasodilatory mechanism. Find on PubMed.
  7. Murata K, Deguchi T, Fujita T, Matsuda H. Improvement in blood fluidity by Kaempferia parviflora rhizome. Journal of Natural Medicines, 2013. Find on PubMed.
  8. Na Takuathung M, Klinjan P, Koonrungsesomboon N. Systematic review and meta-analysis of animal and human studies: metabolic syndrome and erectile dysfunction. Nutrition Research, 2024. Pools the same thin human data; does not add a second controlled trial. Find on PubMed.
  9. Erectile dysfunction as an early marker of cardiovascular disease risk — the broader clinical literature behind the medical-evaluation-first point above. Search PubMed.
  10. Placebo response rates in randomised erectile dysfunction drug trials. Search PubMed.

External Resources

Connections

Back to Table of Contents